Treating Frail Myeloma Patients: AGMT MM04 Shows the Power of Isa-Rd | EHA 2026

Can adding isatuximab to lenalidomide and dexamethasone improve outcomes for older adults with newly diagnosed multiple myeloma?

At EHA 2026, Dr. Heinz Ludwig presents the results of the AGMT MM04 clinical trial, a randomized Phase II study evaluating isatuximab + lenalidomide + dexamethasone (Isa-Rd) followed by isatuximab-lenalidomide maintenance versus standard Rd therapy in transplant-ineligible, elderly patients with multiple myeloma.

Watch to understand why AGMT MM04 is one of the important frontline myeloma studies presented at EHA 2026 and what these findings could mean for personalized treatment of older adults.

Subscribe for more interviews and updates from EHA 2026 covering the latest advances in multiple myeloma research, clinical trials, immunotherapy, CAR T-cell therapy, bispecific antibodies, and emerging treatments.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.